Could Biolinerx Limited Ads (NASDAQ:BLRX) See a Reversal After Less Sellers Came In?

September 17, 2017 - By Clifton Ray

 Could Biolinerx Limited Ads (NASDAQ:BLRX) See a Reversal After Less Sellers Came In?

The stock of Biolinerx Limited Ads (NASDAQ:BLRX) registered a decrease of 52.19% in short interest. BLRX’s total short interest was 384,600 shares in September as published by FINRA. Its down 52.19% from 804,400 shares, reported previously. With 360,800 shares average volume, it will take short sellers 1 days to cover their BLRX’s short positions. The short interest to Biolinerx Limited Ads’s float is 0.67%.

The stock increased 0.96% or $0.01 on September 15, reaching $1.05. About 125,334 shares traded. Bioline RX Ltd (NASDAQ:BLRX) has declined 6.10% since September 17, 2016 and is downtrending. It has underperformed by 22.80% the S&P500.

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. The company has market cap of $109.32 million. The Company’s clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease. It currently has negative earnings.

Bioline RX Ltd (NASDAQ:BLRX) Ratings Coverage

Among 6 analysts covering BioLineRx (NASDAQ:BLRX), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. BioLineRx had 14 analyst reports since July 27, 2015 according to SRatingsIntel. The stock has “Buy” rating by Maxim Group on Thursday, May 18. The company was maintained on Tuesday, August 8 by Oppenheimer. H.C. Wainwright maintained the stock with “Buy” rating in Friday, May 26 report. The stock of Bioline RX Ltd (NASDAQ:BLRX) has “Buy” rating given on Thursday, June 1 by Maxim Group. The rating was initiated by Roth Capital with “Buy” on Thursday, August 3. Maxim Group maintained the stock with “Buy” rating in Monday, July 10 report. The stock of Bioline RX Ltd (NASDAQ:BLRX) earned “Hold” rating by Maxim Group on Friday, August 12. On Monday, July 27 the stock rating was maintained by TH Capital with “Buy”. H.C. Wainwright maintained it with “Buy” rating and $400 target in Wednesday, August 9 report. The company was maintained on Tuesday, August 8 by Maxim Group.

More notable recent Bioline RX Ltd (NASDAQ:BLRX) news were published by: Prnewswire.com which released: “BioLineRx Announces Acquisition of Agalimmune Ltd. to Accelerate Expansion of …” on March 23, 2017, also Seekingalpha.com with their article: “Investors Waiting In BioLineRx” published on July 18, 2017, Seekingalpha.com published: “BioLineRX: Update And Preview Of The Company’s Q4 And FY 2016 Financial …” on March 22, 2017. More interesting news about Bioline RX Ltd (NASDAQ:BLRX) were released by: Seekingalpha.com and their article: “BioLineRx: Expands Cancer Pipeline Significantly By Acquiring Novel Drug …” published on March 27, 2017 as well as Seekingalpha.com‘s news article titled: “BioLineRx: Why I See Significant Upside Potential In This $1 Biotech Stock” with publication date: September 01, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.